Navigation:Home > Radiotherapy > Nasopharyngeal Carcinoma > A new treatment for nasopharyngeal carcinoma: how to apply the experience of head and neck squamous cell carcinoma in nasopharyngeal carcinoma
In the pathogenesis, pathology, treatment of sensitive degree etc. compared with other head and neck squamous cell carcinoma between nasopha
In the pathogenesis, pathology, treatment of sensitive degree etc. compared with other head and neck squamous cell carcinoma between nasopharyngeal carcinoma, in addition to outside Asia in many parts of the world with low incidence of nasopharyngeal carcinoma, clinical trials were difficult, therefore, the results of head and neck squamous cell carcinoma of nasopharyngeal carcinoma for clinical practice. But the other head and neck squamous cell carcinoma and nasopharyngeal carcinoma also have much in common, if the accumulation of head and neck squamous cell carcinoma of evidence-based medicine to do reasonable conversion, used in clinical study of nasopharyngeal carcinoma, nasopharyngeal carcinoma will improve the treatment process for the benefit of patients. In 2009 the progress in the treatment of head and neck squamous cell carcinoma: a meta-analysis combined radiotherapy and chemotherapy treatment on different ways were compared, found that compared with squamous cell carcinoma of head and neck radiotherapy concurrent chemotherapy induced more significant survival benefit and benefit of adjuvant chemotherapy is not obvious; the efficacy of a number of clinical studies also suggest that concurrent chemoradiotherapy for nasopharyngeal carcinoma in the induction or adjuvant chemotherapy combined with radiotherapy. In addition, studies have shown that induction chemotherapy plus concurrent chemoradiotherapy can further improve survival in patients with advanced squamous cell carcinoma of the head and neck, and concurrent chemotherapy and radiotherapy with concurrent chemotherapy and radiotherapy for nasopharyngeal carcinoma have shown a 3 year overall survival benefit. Targeted drugs in the treatment of locally advanced head and neck squamous cell carcinoma has been widely used, the BONNER study demonstrated that compared with radiotherapy alone, radiotherapy combined with cetuximab can prolong cancer local control time, reduce the mortality and improve the patients 5 year survival rate; TREMPLIN study showed that radiotherapy combined with cetuximab treatment induced by chemotherapy the larynx preservation rate and chemotherapy similar adverse reactions are better tolerated and completed the treatment with a higher proportion of EXTREME; research shows that based on platinum + fluorouracil, combined with cetuximab can further improve relapse or metastasis overall survival of patients with head and neck squamous cell carcinoma. But the relative targeting drug clinical research in the treatment of nasopharyngeal carcinoma with less similar results between the past and the target of head and neck squamous cell carcinoma and nasopharyngeal carcinoma to study experience of drug in the treatment of head and neck squamous cell carcinoma, the design of target treatment of nasopharyngeal carcinoma to drugs, the best way to explore the treatment of nasopharyngeal carcinoma.